Oprozomib iramate 20)21/h2-3

20)21/h2-3

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential

and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity

9bR)-6-ethoxy-3a

Oprozomib iramate 20)21/h2-3Oprozomibm, also known as ONX 0912 and PR 047 , is a n orally bioavailable proteasome inhibitor with potential antineoplastic activity. ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and